Scilex Holding (SCLXW) Change in Receivables (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Change in Receivables of -$4.6 million in Q1 2026, down 792.32% quarter-over-quarter from $664000.0 in Q4 2025, and up 70.95% on a YoY basis from -$2.7 million in Q1 2025.
Scilex Holding (SCLXW) Change in Receivables (2022 - 2026) Analysis & Trends
Scilex Holding's Change in Receivables history runs 5 years deep, the most recent figure standing at -$4.6 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 70.95% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$2.6 million (up 44.15% YoY), while the FY2025 annual figure was -$13.8 million, down 320.79% from the prior year.
- Change in Receivables was -$4.6 million for Q1 2026 at Scilex Holding, down from $664000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $18.2 million in Q4 2023 to a low of -$15.8 million in Q1 2025.
- Historically, Change in Receivables has averaged $480117.6 across 5 years, with a median of $664000.0 in 2025.
- Biggest YoY gain for Change in Receivables was 1605.74% in 2023; the steepest drop was 807.75% in 2023.
- A 5-year view of Change in Receivables shows it stood at $3.8 million in 2022, then surged by 382.96% to $18.2 million in 2023, then tumbled by 55.43% to $8.1 million in 2024, then tumbled by 91.8% to $664000.0 in 2025, then slumped by 792.32% to -$4.6 million in 2026.
- The last three Change in Receivables figures came in at -$4.6 million (Q1 2026), $664000.0 (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.60 Mn |
| Mar 31, 2026 | -4.60 Mn |
| Dec 31, 2025 | 664,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Sep 30, 2025 | -4.83 Mn |
| Sep 30, 2025 | -4.83 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | -15.82 Mn |
| Mar 31, 2025 | -15.82 Mn |
| Dec 31, 2024 | 8.10 Mn |
| Dec 31, 2024 | 8.10 Mn |
| Sep 30, 2024 | -5.24 Mn |
| Sep 30, 2024 | -5.24 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Dec 31, 2023 | 18.17 Mn |
| Dec 31, 2023 | 18.17 Mn |